The best thing about EPT is that they are on track for revenue...

The best thing about EPT is that they are on track for revenue this year. That should mean no more capital raisings and then if you want a piece of the action you need to go and buy in the market. This is still going to be a bit of a slow burn but when revenue is getting close then the SP will move up to RAP territory. I am sure some of the other medical tech companies will be looking at EPT as an acquisition possibility, given its relatively short time to revenue and a commercial project. Once they get TGA and FDA approval for the first dementia pain App I will be surprised if a larger medical tech firm does not make a bid for them. It might be later this year or early next year but I am predicting it will come.